Extended interval dosing of natalizumab: More evidence in support

被引：1
|
作者：
Toljan, Karlo [1 ]
Conway, Devon S. [1 ]
机构：
[1] Cleveland Clin, Neurol Inst, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave U10, Cleveland, OH 44195 USA
来源：
NEUROTHERAPEUTICS | 2024年 / 21卷 / 03期
关键词：
Multiple sclerosis; Disease-modifying therapy; Natalizumab; Extended interval dosing;
D O I：
10.1016/j.neurot.2024.e00351
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effectiveness of Natalizumab in Extended Dosing Interval
    Hervas, Jose Vicente
    Punet-Ortiz, Joan
    Teniente-Serra, Aina
    Mansilla, M. Jos
    Quirant-Sanchez, Bibiana
    Navarro, Juan
    Presas, Silvia
    Martinez-Caceres, Eva
    Ramo, Cristina
    NEUROLOGY, 2016, 86
  • [2] Effectiveness of natalizumab in extended dosing interval
    Ramo-Tello, C.
    Grau-Lopez, L.
    Vilaro, L.
    Segui, C.
    Delicado, S.
    Bonafont, X.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 214
  • [3] Extended-interval dosing of natalizumab in NOVA
    Stuve, Olaf
    Tugemann, Bastian
    LANCET NEUROLOGY, 2023, 22 (03): : 199 - 200
  • [4] Efficacy and safety of natalizumab extended interval dosing
    Zeineddine, M.
    Ayyoubi, N.
    Tamim, H.
    Nicolas, J.
    Khoury, S.
    Yamout, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 871 - 871
  • [5] Pharmacodynamics of natalizumab extended interval dosing in MS
    Zhovtis Ryerson, Lana
    Li, Xiaochun
    Goldberg, Judith D.
    Hoyt, Tamara
    Christensen, Angel
    Metzger, Ryan R.
    Kister, Ilya
    Foley, John
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (02):
  • [6] Extended interval dosing of natalizumab: is efficacy preserved?
    Clerico, M.
    Signori, A.
    De Mercanti, S.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Landi, D.
    Mataluni, G.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 282 - 283
  • [7] Extended interval dosing of natalizumab in multiple sclerosis
    Ryerson, L. Zhovtis
    Frohman, T. C.
    Foley, J.
    Kister, I.
    Weinstock-Guttman, B.
    Tornatore, C.
    Pandey, K.
    Donnelly, S.
    Pawate, S.
    Bomprezzi, R.
    Smith, D.
    Kolb, C.
    Qureshi, S.
    Okuda, D.
    Kalina, J.
    Rimler, Z.
    Green, R.
    Monson, N.
    Hoyt, T.
    Bradshaw, M.
    Fallon, J.
    Chamot, E.
    Bucello, M.
    Beh, S.
    Cutter, G.
    Major, E.
    Herbert, J.
    Frohman, E. M.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (08): : 885 - 889
  • [8] Efficacy and safety of natalizumab extended interval dosing
    Zeineddine, Maya
    Ayyoubi, Nabil
    Tamim, Hani
    Nicolas, Johny
    Khoury, Samia
    Yamout, Bassem
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP22 - NP23
  • [9] Efficacy and safety of natalizumab extended interval dosing
    Yamout, Bassem, I
    Sahraian, Mohamad Ali
    El Ayoubi, Nabil
    Tamim, Hani
    Nicolas, Johnny
    Khoury, Samia J.
    Zeineddine, Maya M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 24 : 113 - 116
  • [10] Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users
    Seferoglu, Meral
    Sivaci, Ali Ozhan
    Cinar, Bilge Piri
    Tunc, Abdulkadir
    Bunul, Sena Destan
    Ethemoglu, Ozlem
    Tekan, Ulgen Yalaz
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 975 - 976
12345